Form 4: BridgeBio Pharma Director Fred Hassan Acquires Stock Options

Director Fred Hassan acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Summary

• Fred Hassan, a director of BridgeBio Pharma, Inc., acquired stock options for 26,014 shares on June 21, 2024.
• The exercise price of the stock options is $27.36.
• The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it does indicate confidence from the director in the company's future.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The stock options vest over a three-year period, incentivizing the director to contribute to the company's long-term success.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. Option grants are a common form of executive compensation in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, used to align the interests of management with those of shareholders.
• The vesting schedule of one-third per year is a standard practice, similar to companies like Amgen and Gilead Sciences.
• The size of the grant is relative to the director's role and the overall compensation strategy of BridgeBio Pharma, which would need to be compared to peer companies to assess its competitiveness.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates